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ABSTRACT 
The high mortality rates of pancreatic ductal adenocarcinoma (PDAC) are largely 
attributed to a delayed diagnosis, of which in advanced disease, patients are unable 
to receive surgical resection with curative intent. Clinical presentations and genetic 
features shared between PDAC and other pancreatic conditions such as chronic 
pancreatitis (CP) are insufficient to facilitate the disease and often lead to diagnostic 
uncertainty at an early stage. The purpose of this study was to develop sensitive and 
specific non-invasive markers to aid in the detection and disease monitoring of PDAC. 
Here, circulating cell-free DNA (cfDNA) isolated from plasma samples of patients with 
PDAC (n= 155) and two control groups consisting of patients with either CP (n= 46) or 
critical limb ischemia (CLI) (n= 88) revealed significant differences in measured 
concentrations between the three patient groups (p= 0.006-Kruskal-Wallis test).When 
two groups were compared with each other using the Wilcoxon rank-sum test, 
observable differences were seen between the two pancreatic diseases: PDAC and 
CP (p= 0.002), and between the two controls: CP and the CLI groups (p= 0.007). A 
strong association was also observed in elevated cfDNA levels of CLI patients with 
HIV (p= 0.03), indicating a poor prognosis for patients. Results from methylation-
specific PCR (MSP) in age-matched patient samples showed promoter methylation to 
account for the loss of Smad4 in late-stage PDAC; with an observed association with 
overall increasing cfDNA levels (p= 0.03).This study indicates the potential clinical 
utility of cfDNA as a non-invasive tool to predict disease progression both 
quantitatively and qualitatively, as well as to trace epigenetic changes in tumour 
markers associated with PDAC. Further investigation to identify hypermethylated 
genes in cfDNA for the early detection of PDAC is warranted. 
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